Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non Operating Income (2016 - 2025)

Historic Non Operating Income for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$77000.0.

  • NovaBay Pharmaceuticals' Non Operating Income changed N/A to -$77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$243000.0, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$550000.0 for FY2024, which is 4905.15% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Non Operating Income of -$77000.0 as of Q3 2025.
  • NovaBay Pharmaceuticals' Non Operating Income's 5-year high stood at $63000.0 during Q4 2023, with a 5-year trough of -$1.6 million in Q4 2021.
  • For the 5-year period, NovaBay Pharmaceuticals' Non Operating Income averaged around -$245416.7, with its median value being -$87000.0 (2024).
  • Examining YoY changes over the last 5 years, NovaBay Pharmaceuticals' Non Operating Income showed a top increase of 16428.57% in 2023 and a maximum decrease of 1430000.0% in 2023.
  • NovaBay Pharmaceuticals' Non Operating Income (Quarter) stood at -$1.6 million in 2021, then skyrocketed by 93.79% to -$98000.0 in 2022, then skyrocketed by 164.29% to $63000.0 in 2023, then tumbled by 253.97% to -$97000.0 in 2024, then increased by 20.62% to -$77000.0 in 2025.
  • Its Non Operating Income was -$77000.0 in Q3 2025, compared to -$97000.0 in Q4 2024 and -$69000.0 in Q2 2024.